pHion Therapeutics is a UK based biotech delivering ground-breaking nucleic acid vaccines and therapeutics. Our technology uses the proprietary RALA peptide-based drug delivery system and our vision is to develop advanced therapeutics for global patient benefit in cancer and infectious disease.  

Our lead product is a therapeutic vaccine against human papillomavirus (HPV) driven cancers. pHion’s pipeline programs also include therapeutic vaccines against ovarian cancer and prostate cancer, and a prophylactic vaccine against Crimean-Congo Haemorrhagic Fever.

The company is headquartered in Belfast, Northern Ireland. invoX Pharma is the majority shareholder of pHion Therapeutics.